FAK antibody | knockout validation | Millipore 05-537

This is a knockout-validated antibody summary, based on the publication "FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG1

Company: Millipore

Antibody: FAK

Catalog number: 05-537

Summary: Mouse monoclonal IgG1 against a fusion protein corresponding to residues 1-423 of human FAK. Reacts with human, mouse and rat. Suitable for western blot, immunohistochemistry, and immunoprecipitation.

Validation Method

Western blot

Sample

Control and FAK−/− mouse endothelial fibroblasts (MEFs). Cell lysates were isolated using RIPA (10 mM Tris base pH 7.2, 150 mM NaCl, 1% Na-deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS)) supplemented with protease inhibitors (Sigma), phosphatase inhibitors (Sigma) and phenylmethanesulfonyl fluoride.

Primary incubation

Used according to manufacturer’s recommended conditions.

Secondary incubation

Used according to manufacturer’s recommended conditions.

Detection

Luminata Classico or Crescendo ECL (EMD Millipore).

Figure

Immunoblotting for Y397 FAK and total FAK on SK-NEP-1 and G401 renal tumor cell lysates. Lysates from mouse endothelial fibroblasts with (MEFFAK+/+) and without (MEFFAK−/−) FAK served as controls. Please see Figure 1c in the article [1].

Clone note

The same clone (4.47) is sold as LifeSpan Biosciences LS-B212; Abnova MAB12511; EMD Millipore 05-537, 16-234, 16-233, 16-173.

References
  1. Megison M, Gillory L, Stewart J, Nabers H, Mrozcek-Musulman E, Beierle E. FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors. Mol Cancer Res. 2014;12:514-26 pubmed publisher